Trials / Unknown
UnknownNCT02282267
Blood Detection of EGFR Mutation For Iressa Treatment
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 188 (actual)
- Sponsor
- Peking University Cancer Hospital & Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study was proposed to validate the efficacy of gefitinib as first-line therapy in advanced lung adenocarcinoma with EGFR mutation determined by plasma cf-DNA.
Detailed description
Patients without enough tissue for EGFR mutation detection can also have opportunity to use EGFR-TKI as first line therapy. Meanwhile, this study was also proposed to explore the best intervention time of anti-resistant drugs (such as AZD 9291, a T790M inhibitor) through the quantitative and dynamic analysis of EGFR sensitive and resistant mutation in plasma cf-DNA during EGFR-TKI treatment process.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gefitinib | Iressa 250mg oral daily |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2017-12-01
- Completion
- 2018-02-01
- First posted
- 2014-11-04
- Last updated
- 2017-02-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02282267. Inclusion in this directory is not an endorsement.